Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 301 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Tackling under-representation of Black data scientists in cancer research November 7, 2022 On Giving Tuesday, You Helped Us Raise $334,449 For People, Pets,... December 13, 2019 Immunotherapy, Liquid Biopsy, and Treatment Combinations: Research from the 2024 ASCO... January 18, 2024 Getting cancer services back on track during the COVID-19 pandemic June 22, 2020 Load more HOT NEWS How to Talk About Cancer With Someone Who Has It Airline Won’t Let Dad And Newborn On Plane, So Kind Stranger... BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing... Dabrafenib–Trametinib Combination Approved for Solid Tumors with BRAF Mutations
